Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
ISRCTN42054893Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of romidepsin and carfilzomib in peripheral T-cell lymphoma (PTCL), sponsored by University of Birmingham. Primary endpoints: Maximum Tolerated Dose (MTD) of romidepsin and carfilzomib combination and Best Overall Response Rate. Started Jul 2015; status: completed.
02
Drugs
romidepsincarfilzomib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ISRCTN42054893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42054893.